Clinical Trial Update: Assessment of an Early De-Escalation to a Low-potency Single Antiplatelet Therapy Guided by Genetics Versus a Systematic High-Potency Single Antiplatelet Therapy to Neutralize Bleeding Complications in Patients With High Bleeding Risk Beyond One Month After an Acute Coronary Syndrome [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial compares genetically guided de-escalation to a low-potency antiplatelet therapy versus a systematic high-potency antiplatelet approach …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome
• Myocardial Infarction

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: MYOCARDIAL INFARCTION | Phase 3 | Status: RECRUITING